What is the probability of transmitting genital herpes during sexual activity with visible lesions compared to without lesions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Transmission Risk of Genital Herpes With and Without Visible Lesions

Herpes transmission occurs frequently during asymptomatic periods without visible sores—accounting for approximately 70% of transmissions—though the absolute risk per sexual encounter is higher when lesions are present.

Transmission Dynamics

With Visible Lesions (Symptomatic Shedding)

When active genital lesions or prodromal symptoms are present, viral shedding is at its peak and transmission risk is substantially elevated. The CDC guidelines explicitly recommend abstaining from all sexual activity when lesions or prodromal symptoms are present 1. In documented transmission events, approximately 30% occurred when source partners had recognized lesions or prodrome 2.

Without Visible Lesions (Asymptomatic Shedding)

The more concerning clinical reality is that most transmission (approximately 70%) occurs during asymptomatic viral shedding when neither partner recognizes active disease 2. This asymptomatic transmission is well-documented across multiple studies and represents the primary mechanism by which genital herpes spreads in populations 1, 3.

Quantified Transmission Rates

The annual transmission risk varies significantly by several factors:

Gender-specific risk:

  • Female partners acquiring from infected males: 10-32% per year (higher in HSV-1/HSV-2 seronegative women at 31.8% annually) 2, 4
  • Male partners acquiring from infected females: <5% per year 2, 5

Prior HSV-1 infection provides partial protection: Women with existing HSV-1 antibodies have approximately 9.1% annual acquisition risk versus 31.8% in completely seronegative women 2.

Critical Clinical Context

Asymptomatic Shedding Patterns

  • HSV-2 sheds more frequently asymptomatically than HSV-1 1
  • Asymptomatic shedding is more frequent in the first 12 months after infection 1
  • Many infected individuals (60-90%) are unaware they have genital herpes and unknowingly transmit infection 1, 5

Risk Reduction Strategies

Suppressive antiviral therapy (valacyclovir 500 mg daily) reduces HSV-2 transmission to susceptible heterosexual partners by approximately 50% by decreasing asymptomatic viral shedding 6. However, it does not eliminate transmission risk entirely 1.

Consistent condom use reduces but does not eliminate transmission risk, as HSV can be shed from areas not covered by condoms 1, 7.

Common Pitfalls

  1. Falsely reassuring patients that absence of lesions means no transmission risk—this is the most dangerous misconception, as most transmission occurs asymptomatically

  2. Failing to counsel that many infected individuals have unrecognized or atypical symptoms—at least half of seropositive individuals can learn to recognize previously unnoticed recurrences 5

  3. Not discussing the higher risk to female partners—women face 3-6 times higher acquisition risk than men in heterosexual relationships 2, 5

  4. Assuming HSV-1 genital infection carries the same recurrence and transmission risk as HSV-2—genital HSV-1 recurs much less frequently 1

The evidence consistently demonstrates that while visible lesions increase per-contact transmission probability, the majority of herpes transmission occurs during the far more frequent periods of asymptomatic viral shedding 1, 2, 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.